Q3 FY2026 · ended Sep 30, 2026 · Revenue $25.75M, -63.5% YoY · Filed Nov 4, 2026
Viridian Therapeutics, Inc./DE (VRDN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $25.8 million and a net loss of $101.2 million. Free cash flow was -$93.1 million. As of Sep 30, 2026 it held $955.2 million in cash and investments and $806,000 in total debt.
Revenue
$25.75M
-63.5% vs year-ago quarter
Net income
$-101.21M
-192.5% vs year-ago quarter
Operating cash flow
$-92.77M
-9.6% vs year-ago quarter
Free cash flow
$-93.14M
-9.9% vs year-ago quarter
EPS
—
Dividend per share
None
Shares outstanding
113.56M
+19.0% vs year-ago quarter
Net cash
$954.40M
Q3 FY2026
Operating margin
-1781.4%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRDN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1590750
- Former names
- MIRAGEN THERAPEUTICS, INC. (until Jan 15, 2021); SIGNAL GENETICS, INC. (until Feb 10, 2017); SIGNAL GENETICS LLC (until Jul 9, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $25.8M | $284,000 | $141,000 | $132,000 | $70.6M |
| Operating income | -$103.5M | -$126.3M | -$116.2M | -$122.7M | -$40.0M |
| Net income | -$101.2M | -$127.1M | -$104.9M | -$120.4M | -$34.6M |
| Operating cash flow | -$92.8M | -$105.3M | -$119.7M | -$23.8M | -$84.6M |
| Free cash flow | -$93.1M | -$106.6M | -$119.7M | -$24.0M | -$84.7M |
| Total assets | $1.0B | $1.1B | $789.0M | $899.4M | $577.1M |
| Total liabilities | $448.0M | $435.1M | $153.0M | $177.3M | $74.2M |
| Stockholders' equity | $580.7M | $662.1M | $636.0M | $722.2M | $503.0M |
| Cash and investments | $955.2M | $816.5M | $585.8M | $662.3M | $321.3M |
| Total debt | $806,000 | $722,000 | $738,000 | $2.7M | $23.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 29, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2026 | Jun 2, 2026 |
All 817 Viridian Therapeutics, Inc./DE SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.